首页> 外文期刊>Journal of viral hepatitis. >Quantitative assessment of hepatitis C virus RNA in peripheral blood mononuclear cells during therapy with interferon-alpha2a.
【24h】

Quantitative assessment of hepatitis C virus RNA in peripheral blood mononuclear cells during therapy with interferon-alpha2a.

机译:干扰素-α2a治疗期间外周血单个核细胞中丙型肝炎病毒RNA的定量评估。

获取原文
获取原文并翻译 | 示例
           

摘要

A significant number of patients with hepatitis C (HCV) treated with interferon (IFN) will initially clear their serum of HCV RNA, but will then have recurrence of viraemia either during or after therapy. One proposed mechanism for relapse is that HCV may persist in peripheral blood mononuclear cells (PBMCs) and that the PBMCs serve as a 'viral reservoir' that is resistant to IFN. To address this hypothesis, we performed serial, quantitative polymerase chain reaction (PCR) of HCV RNA in serum and PBMCs from 26 consecutive patients treated with IFN-alpha2a. Of the 26 patients, 11 (42%) did not clear virus from their serum during therapy and were termed non-responders. Five patients (19%) had sustained clearance of virus from serum and were termed complete responders. The remaining 10 patients (39%) initially eliminated HCV RNA from their serum, but had relapse of viraemia. They were termed partial responders. In all 10 partial responders HCV RNA was undetectable in PBMCs at the same time that it was undetectable in serum. When virus recurred in serum, it was preceded by or occurred at the same time as the return of virus in PBMCs. The results of our study indicate that PBMCs did not serve as an IFN-resistant 'viral reservoir' during therapy. Partial responders who transiently cleared virus from serum also cleared virus from PBMCs and the presence or titre of HCV RNA in PBMCs at the initiation of therapy did not predict response to therapy.
机译:大量接受干扰素(IFN)治疗的丙型肝炎(HCV)患者最初会清除血清中的HCV RNA,但随后会在治疗期间或之后复发病毒血症。一种建议的复发机制是HCV可能在外周血单核细胞(PBMC)中持续存在,并且PBMC充当了对IFN有抗药性的“病毒库”。为了解决这个假设,我们对来自连续26例接受IFN-alpha2a治疗的患者的血清和PBMC中的HCV RNA进行了定量定量聚合酶链反应(PCR)。在26例患者中,有11例(42%)在治疗过程中没有从血清中清除病毒,被称为无反应者。五名患者(19%)从血清中持续清除病毒,被称为完全缓解者。其余10名患者(39%)最初从其血清中清除了HCV RNA,但病毒血症复发。他们被称为部分响应者。在所有10个部分反应者中,在血清中均未检测到PBMC中的HCV RNA。当病毒在血清中复发时,它是在PBMC中病毒传播之前或同时发生。我们的研究结果表明,PBMCs在治疗过程中不能作为抗IFN的“病毒库”。暂时从血清中清除病毒的部分反应者也从PBMC中清除了病毒,并且在治疗开始时PBMC中HCV RNA的存在或滴度无法预测对治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号